Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Martin-Broto

Showing results (21-30 of 117) with videos related to

Pageof 12
Sort By:
Annals of Medicine|October 13, 2025
Spatial immunoprofiling of retroperitoneal leiomyosarcomas reveals intratumoral heterogeneity in immune cell infiltration, checkpoint molecule expression, and tertiary lymphoid structuresIva Benesova, Jan Balko, Vira Tovazhnianska, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 7, 2021
Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter studySylvie Bonvalot, Jay Wunder, Alessandro Gronchi, et al.
Critical Reviews in Oncology/Hematology|January 17, 2025
Preclinical models of soft tissue sarcomas - generation and applications to enhance translational researchSandro Pasquali, David S Moura, Molly R Danks, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2025
Identification of BET Inhibitors (BETi) Against Solitary Fibrous Tumor (SFT) Through High-Throughput Screening (HTS)Jose L Mondaza-Hernandez, David S Moura, Yi Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2024
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS)Javier Martin-Broto, Roberto Diaz-Beveridge, David Moura, et al.
Neoplasia (New York, N.Y.)|October 30, 2025
Identification of BET inhibitors (BETi) against solitary fibrous tumor (SFT) through high-throughput screening (HTS)Jose L Mondaza-Hernandez, David S Moura, Yi Li, et al.
Nature Communications|January 20, 2026
Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma studyJavier Martin-Broto, Antonio Casado, Gloria Marquina, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2015
Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)Xavier Garcia del Muro, Enrique de Alava, Vicenç Artigas, et al.
Acta Oncologica (Stockholm, Sweden)|May 20, 2014
Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II studyJavier Martin-Broto, Charles S Cleeland, Paul A Glare, et al.
Cancers|June 13, 2025
Rethinking the Prognostic Role of Necrosis in Soft-Tissue Sarcoma: Multidisciplinary Insights from the Sarcoma AcademyBeata Bode-Lesniewska, Hans Roland Dürr, Dian Wang, et al.
Pageof 12

Showing results (21-30 of 117) with videos related to

Sort By:
Pageof 12
Annals of Medicine|October 13, 2025
Spatial immunoprofiling of retroperitoneal leiomyosarcomas reveals intratumoral heterogeneity in immune cell infiltration, checkpoint molecule expression, and tertiary lymphoid structuresIva Benesova, Jan Balko, Vira Tovazhnianska, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 7, 2021
Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter studySylvie Bonvalot, Jay Wunder, Alessandro Gronchi, et al.
Critical Reviews in Oncology/Hematology|January 17, 2025
Preclinical models of soft tissue sarcomas - generation and applications to enhance translational researchSandro Pasquali, David S Moura, Molly R Danks, et al.
Biorxiv : the Preprint Server for Biology|April 8, 2025
Identification of BET Inhibitors (BETi) Against Solitary Fibrous Tumor (SFT) Through High-Throughput Screening (HTS)Jose L Mondaza-Hernandez, David S Moura, Yi Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2024
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS)Javier Martin-Broto, Roberto Diaz-Beveridge, David Moura, et al.
Neoplasia (New York, N.Y.)|October 30, 2025
Identification of BET inhibitors (BETi) against solitary fibrous tumor (SFT) through high-throughput screening (HTS)Jose L Mondaza-Hernandez, David S Moura, Yi Li, et al.
Nature Communications|January 20, 2026
Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma studyJavier Martin-Broto, Antonio Casado, Gloria Marquina, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2015
Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)Xavier Garcia del Muro, Enrique de Alava, Vicenç Artigas, et al.
Acta Oncologica (Stockholm, Sweden)|May 20, 2014
Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II studyJavier Martin-Broto, Charles S Cleeland, Paul A Glare, et al.
Cancers|June 13, 2025
Rethinking the Prognostic Role of Necrosis in Soft-Tissue Sarcoma: Multidisciplinary Insights from the Sarcoma AcademyBeata Bode-Lesniewska, Hans Roland Dürr, Dian Wang, et al.
Pageof 12